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ABSTRACT
A retrospective analysis of hospital laboratory
databases for 2000–2003 found that 0.4–1.0% of
methicillin-resistant Staphyloccus aureus isolates
had an antibiotic susceptibility pattern associated
previously with the production of Panton–Valen-
tine leukocidin (PVL). Of 81 isolates of this type,
35 were available for molecular testing. Each of
the 35 available isolates carried the PVL genes,
and 33 of these 35 isolates had an identical SmaI
pulsed-field gel electrophoresis pattern.
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Methicillin-resistant Staphylococcus aureus (MRSA)
has spread worldwide, mainly by clonal diffu-
sion. Until recently, MRSA was considered to be
almost exclusively a nosocomial pathogen, and
transmission in the community was infrequent.
Most cases of community-acquired MRSA
(CA-MRSA) had risk-factors linked to hospital
or medical care [1,2]. However, concerns have
been raised about MRSA epidemics in Australian
aboriginal populations, native Americans, pri-
son inmates and sports teams [3–6]. MRSA
strains spreading in these settings are genetically
unrelated to hospital-acquired MRSA strains
(HA-MRSA), and belong to a few pulsed-field
gel electrophoresis (PFGE) types with a clear
continental distribution [7]. For example, the ‘type
A’ PFGE pattern corresponds to the major Euro-
pean clone, whereas the ‘type B’ pattern corres-
ponds to one of the most frequent clones
in the USA. The antibiotic resistance pattern of
CA-MRSA also differs from that of HA-MRSA,
with the most frequent resistance pattern des-
cribed to date in Europe [7–11] showing hetero-
geneous resistance to methicillin, susceptibility to
gentamicin, tobramycin and fluoroquinolones,
and resistance to fusidic acid and kanamycin. In
general, HA-MRSA strains recovered in France
and other European countries are resistant to
kanamycin, tobramycin and fluoroquinolones,
with resistance to gentamicin varying according
to local epidemiology [12,13].
In addition to antibiotic resistance, CA-MRSA
strains can harbour the Panton–Valentine leukoc-
idin (PVL) genetic determinant [7,10,11].
PVL-MRSA has been isolated from furuncles,
cutaneous abscesses and necrotising pneumonia,
mainly in young children [10,14–16]. More
recently, PVL-MRSA strains have been implicated
in nosocomial cross-transmission [11,17], but
although epidemics have been reported in the
USA and many European countries, the real
magnitude of the problem is unknown. Therefore,
the present study evaluated retrospectively the
proportion of PVL-MRSA among MRSA isolates
in France, and investigated the characteristics of
patients referred to hospital.
The databases for 2000–2003 of hospital labor-
atories participating in ONERBA (National
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Observatory for Epidemiology of Bacterial Resist-
ance to Antibiotics; http://www.onerba.org)
were analysed retrospectively for the presence of
the typical antibiotic susceptibility pattern of the
most frequent French PVL-producing CA-MRSA
strains (see above). Only clinical isolates were
included, and duplicates were excluded. All
laboratories followed the antibiotic susceptibility
testing guidelines of the French Society for Micro-
biology. Basic demographic and clinical informa-
tion was collected for each isolate matching the
defined CA-MRSA susceptibility profile. When
available, each isolate was tested for the mecA and
PVL genes [7], and was analysed by PFGE
following SmaI macrorestriction [7].
In total, 12 laboratories (seven teaching hospi-
tals, four general hospitals and one military
hospital), accounting for a total of 13 767 acute-
care beds, and located in seven of the 22 French
regions, participated in the study. Only half had
an accessible database for 2000. Among the 12
hospitals, eight had a paediatric ward with a
paediatric outpatient clinic, 11 had an obstetric
ward, and 11 had an emergency room (ER) open
for 24 h daily. Hospital bed numbers varied
between 292 and 2389. In total, 36 825 S. aureus
isolates and 11 395 (30.9%) MRSA isolates were
obtained from clinical samples during the 4-year
study period. The mean proportion of MRSA
isolates with the CA-MRSA susceptibility pattern
was 0.7% (n = 81), and ranged from 0.4% (in
2000) to 1.0% (in 2001). Only two of the 12
hospitals did not isolate any MRSA strains with
the CA-MRSA pattern. These two hospitals had
the lowest number of beds among the 12 hospi-
tals, did not have a paediatric ward, and isolated
the smallest number of MRSA strains annually.
One hospital reported that 4.3% and 3.7% of
MRSA isolates had the CA-MRSA pattern in 2001
and 2002, respectively, while seven of the nine
remaining hospitals had a CA-MRSA proportion
of < 1.5% from 2000 to 2003. It is of interest that
one hospital was able to analyse its 1994–1999
databases, and a suspect isolate was recovered as
early as 1997 from a male aged 33 years who was
treated for a finger infection.
The characteristics of patients harbouring
CA-MRSA are given in Table 1. None of the eight
isolates in 2000 from six hospitals was available.
Of 73 suspected CA-MRSA isolates from 2001 to
2003 in the 12 hospitals, 35 (47.9%) were available
for molecular testing. All 35 isolates were mecA-
positive and PVL-positive, and all but two
belonged to European PFGE pattern A [7]; the
two remaining isolates belonged to PFGE pattern
B, found preferentially in the USA. The two latter
isolates were from the same hospital, but no
epidemiological link with the USA or between the
two patients could be found. Only one of the two
isolates was resistant to erythromycin. There were
no significant differences in age, gender, type of
sample or ward, and the number of days between
hospitalisation ⁄ consultation and isolation of
MRSA between patients with isolates tested for
PVL and those with isolates not available for
testing.
PVL-MRSA has been linked mainly to out-
breaks in closed communities, but has also been
isolated from nosocomial infections [4,6,17]. PVL-
MRSA represented < 1.0% of MRSA isolates in
French hospitals between 2000 and 2003. How-
ever, three of the 12 hospitals reported propor-
tions > 2%. Such higher proportions may be
linked to community outbreaks because most
isolates were from outpatient clinics or ERs.
Physicians involved in patient management in
an ER should be aware of the possibility of
CA-MRSA, and should request culture for necro-
tising skin lesions. No specific age group or
Table 1. Characteristics of 81 patients with methicillin-
resistant Staphylococcus aureus suspected of producing
Panton–Valentine leukocidin
Characteristic n %
Age (years)
0–4 15 18.5
5–14 6 7.4
15–24 13 16.1
25–64 29 35.8
> 64 18 22.2
Male 44 54.3
Origin of sample
Cutaneous abscess 18 22.2
Superficial cutaneous lesion 51 63.0
Vaginal or vulvar lesion 4 4.9
Blood culture 3 3.7
Respiratory tract 3 3.7
Occular disease 2 2.5
Type of department
Emergency room 16 19.7
Medical 14 17.3
Surgical 33 40.7
Paediatric 14 17.3
Obstetric 4 4.9
Days between hospitalisation or
consultation and isolation
0 54 66.7
1 or 2 14 17.2
> 2 13 16.1
Other antibiotic resistance in S. aureus isolates
Erythromycin 16 19.8
Tetracycline (65 isolates tested) 59 90.8
586 Clinical Microbiology and Infection, Volume 11 Number 7, July 2005
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 11, 577–596
population could be defined, although there was
a slight tendency towards younger age groups or
closed communities in previous reports. How-
ever, the most severe cases will be more likely to
visit an ER, while less serious infections will be
unreported. A prospective study, with systematic
sampling of all necrotic infections occurring in the
community, may be necessary to address this
issue.
Although not all isolates were available for
testing, the fact that all isolates tested for the PVL
genes were positive suggests that the delineating
antibiotic susceptibility pattern is highly related
to PVL-producing CA-MRSA. The National Ref-
erence Centre tested > 100 HA-MRSA isolates
from various geographical origins in France dur-
ing the same period of time and did not identify
any PVL-producing MRSA isolates (unpublished
data). Therefore, the proportion of PVL-MRSA
isolates in French hospitals observed in the
present study is likely to be representative. The
fact that almost 84% of specimens were taken
upon admission suggested acquisition in the
community. CA-MRSA may be implicated more
often in nosocomial outbreaks in the near future,
especially if community outbreaks, followed by
increased hospital admissions of patients with
severe necrotising skin lesions, are not curbed.
In conclusion, the present data do not indicate a
major outbreak of CA-MRSA in the community in
France during the last 3 years. However, a retro-
spective survey has recently suggested a high
prevalence of CA-MRSA in necrotic cutaneous
lesions in the USA [16]. Surveillance of CA-MRSA
should therefore be intensified in order to report
outbreaks in a timely manner, since this may have
a direct impact on the design of antibiotic regi-
mens for these types of infections.
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